Efficacy of Purified Borrelial Lipoproteins (PBL) as an oral formulation in reducing transmission of Lyme spirochetes from reservoir hosts to Ixodes scapularis ticks

This study demonstrates that an oral formulation of Purified Borrelial Lipoproteins combined with a recombinant fusion protein adjuvant (PBL+rCOM) effectively induces durable immunity in mouse and white-footed mouse reservoirs, significantly reducing *Borrelia burgdorferi* burden and blocking transmission to *Ixodes scapularis* ticks.

The Gist

The "Lyme Disease Lockdown": A New Strategy to Stop the Bug at the Source

Imagine Lyme disease as a relay race. The baton is the bacteria (Borrelia burgdorferi), and the runners are ticks. The race starts in the woods with a tiny mouse (the reservoir host). The mouse passes the baton to a baby tick (larva). The baby tick grows up, molts into a teenager (nymph), and then passes the baton to a human. Once the human gets the baton, they get sick.

For years, scientists have tried to stop the race by giving humans a vaccine (stopping the human runner) or by killing the ticks (stopping the runners). But this paper proposes a clever new idea: Stop the race before it even starts by vaccinating the mouse.

Here is how the researchers did it, explained simply:

1. The "All-You-Can-Eat" Antigen Buffet (PBL)

Usually, vaccines use just one or two specific parts of a germ to teach the immune system what to look for. Think of it like showing a police officer a photo of a suspect's nose. If the suspect wears a hat, the officer might miss them.

The researchers used something called Purified Borrelial Lipoproteins (PBL). Instead of just one photo, they took the entire bacteria, broke it open, and gave the mouse's immune system a "buffet" of every single protein on the bacteria's surface. It's like showing the police officer a 360-degree video of the suspect, including their clothes, shoes, and hat. This ensures the immune system recognizes the bacteria no matter how it tries to hide.

2. The "Trojan Horse" Delivery System (Oral Vaccination)

You can't just throw a vaccine into a forest and hope a mouse eats it. Plus, if you give a mouse a pill, its stomach acid might destroy the vaccine before it works.

The researchers created an oral vaccine. They mixed the "buffet" (PBL) with a special helper called rCOM.

• The Helper (rCOM): This is a smart delivery truck. It has three parts:
  1. Cholera Toxin B: A "key" that unlocks the door to the mouse's gut immune system.
  2. OspA: A familiar face that the immune system already knows how to fight.
  3. M-Cell Peptide: A GPS signal that guides the vaccine directly to the "M-cells" in the gut, which are like specialized mailboxes that deliver packages straight to the immune system's headquarters.

By feeding this mixture to the mice, the vaccine bypasses the stomach acid and wakes up the immune system right where it needs to be.

3. The Results: A "Transmission Blockade"

The researchers tested this on two types of mice:

• Lab Mice (C3H/HeN): The standard test subjects.
• Wild Mice (White-footed mice): The actual "reservoir" that lives in the woods and spreads Lyme disease to real ticks.

What happened?

• The Immune System Woke Up: The vaccinated mice produced a massive army of antibodies (soldiers) and T-cells (generals) ready to fight.
• The Ticks Got Nothing: When unvaccinated mice were bitten by baby ticks, the ticks picked up the bacteria and became infected. But when vaccinated mice were bitten, the baby ticks ate the blood, but the antibodies in the blood killed the bacteria immediately. The ticks went hungry for the disease.
• The Chain Was Broken: Because the baby ticks didn't get infected, they didn't pass the disease to the "teenager" ticks (nymphs). Consequently, the nymphs couldn't infect humans or other animals.

4. The Secret Ingredient: Salt

Interestingly, the researchers found that adding a little extra salt to the vaccine mixture made it work even better. It's like adding a pinch of salt to a soup to bring out the flavor; the salt helped the immune system recognize the vaccine more clearly. They also checked if feeding the mice a high-salt diet would hurt them, and it didn't—the vaccine still worked perfectly.

5. Why This Matters

This is a game-changer for a few reasons:

• It's a "Herd Immunity" Strategy: Instead of trying to vaccinate every human (which is hard and expensive), you vaccinate the wild animals that carry the disease. If you stop the disease in the woods, it never reaches the humans.
• Long-Lasting: A single dose of this oral vaccine protected the mice for up to 10 months.
• Safe and Simple: It's an oral bait. You could theoretically put this vaccine in a pellet and scatter it in the woods. The mice eat it, get vaccinated, and the cycle of infection is broken.

The Bottom Line

Think of this vaccine as a security system for the forest. Instead of trying to catch the burglar (the tick) every time it tries to break into a house (a human), this vaccine locks the front door of the neighborhood (the mouse population). If the burglar can't get in to steal the goods (the bacteria), the whole neighborhood stays safe.

This study proves that by feeding a smart, salt-enhanced, "buffet-style" vaccine to wild mice, we can stop Lyme disease from ever reaching us.

Technical Summary

1. Problem Statement

Lyme disease (LD), caused by Borrelia burgdorferi (Bb), is the most prevalent tick-borne disease in the US. Current control strategies face significant limitations:

• Lack of Human Vaccines: No approved human vaccine exists, and candidates like VLA15 are still in development.
• Treatment Limitations: Antibiotics (e.g., doxycycline) are effective but do not prevent Post-Treatment Lyme Disease Syndrome (PTLDS).
• Enzootic Cycle: Bb transmission relies on a complex cycle involving the Ixodes scapularis tick and vertebrate reservoir hosts (primarily the white-footed mouse, Peromyscus leucopus). Since there is no transovarial transmission, naïve larvae acquire Bb from infected reservoirs.
• Vaccine Gaps: Existing reservoir-targeted vaccines often rely on single antigens (e.g., OspA), suffer from antigenic diversity issues (e.g., OspC), or require live delivery vectors with safety concerns. There is a critical need for a multi-antigen, oral, reservoir-targeted biologic that blocks transmission at the source.

2. Methodology

The study developed and evaluated an oral vaccine platform using Purified Borrelial Lipoproteins (PBL) combined with a novel recombinant adjuvant.

• Antigen Preparation (PBL): Lipoproteins were extracted from B. burgdorferi strain B31-A3 using Triton X-114 detergent phase separation. This method enriched surface-expressed lipoproteins (including OspA, OspB, OspC, OspD, LP6.6) while removing non-lipoproteins like FlaB (flagellin).
• Adjuvant Design (rCOM): A recombinant fusion protein was engineered containing:
  • Cholera Toxin B subunit (CTB): A mucosal adjuvant to stimulate immune responses.
  • Outer Surface Protein A (OspA): A key protective antigen.
  • M-cell targeting peptide (C2X): Two tandem repeats of a peptide targeting Microfold (M) cells in Peyer's patches to enhance antigen uptake.
  • Note: A control fusion without CTB was termed rOM.
• Delivery Systems: Various oral formulations were tested, including:
  • PBL alone.
  • PBL encapsulated in chitosan-PEG-PLGA nanoparticles.
  • PBL delivered via ragweed pollen grains.
  • PBL combined with rCOM (PBL+rCOM).
  • Buffer optimization (varying NaCl concentration).
• Animal Models:
  • C3H/HeN Mice: Used for initial immunogenicity and efficacy screening.
  • Peromyscus leucopus (White-footed mice): The natural reservoir host, used to validate efficacy in a biologically relevant model.
• Experimental Design:
  • Mice were immunized orally (gavage) or intradermally.
  • Hosts were challenged with Bb (needle inoculation or infected nymphs).
  • Transmission Blocking Assay: Naïve I. scapularis larvae were fed on vaccinated hosts. The burden of Bb in fed larvae, molted nymphs, and subsequent naïve hosts was quantified via qPCR (targeting flaB and ospA) and culture in BSK-II media.
  • Long-term Studies: Protection was assessed up to 10 months post-vaccination.

3. Key Contributions

• Novel Antigen Platform: The study validates PBL (a mix of native lipoproteins) as a superior antigen source compared to single recombinant proteins, offering a broader immune response against both tick-phase (OspA) and host-phase (OspC) antigens.
• Oral Adjuvant Strategy: The development of rCOM (CTB-OspA-M-cell peptide) as a mucosal adjuvant that, when combined with PBL, induces durable immunity via the oral route without live vectors.
• Buffer Optimization: Discovery that high-salt buffer (300 mM NaCl) significantly enhances the immunogenicity of the oral formulation in P. leucopus.
• Reservoir-Targeted Proof-of-Concept: Demonstrated that a single oral dose can block transmission for up to 10 months, disrupting the enzootic cycle.

4. Key Results

Immunogenicity and Protection in C3H/HeN Mice

• Antibody Response: Oral administration of PBL alone induced some antibodies, but PBL+rCOM elicited robust, durable systemic (IgG1, IgG2a, IgG2b) and mucosal (IgA) responses.
• T-Cell Response: Vaccination induced significant Th1 (IFN-γ) and Th2 (IL-4) memory T-cell responses at days 28 and 65.
• Transmission Blocking:
  • Larvae feeding on PBL+rCOM vaccinated mice showed significantly reduced Bb burden compared to controls.
  • In some groups, Bb was undetectable in fed larvae and molted nymphs.
  • Nymphs derived from vaccinated hosts failed to transmit Bb to naïve mice.
• Durability: A single oral dose of PBL+rCOM provided protection for up to 10 months, significantly reducing Bb acquisition by larvae and tissue burden.
• Formulation Specifics: Nanoparticle encapsulation alone did not significantly improve efficacy over PBL alone. However, the combination of PBL + rCOM was essential; rCOM alone was insufficient.

Efficacy in Natural Reservoir (P. leucopus)

• Cross-Species Efficacy: PBL+rCOM induced strong antibody responses and reduced Bb burden in P. leucopus, confirming efficacy in the natural host.
• Sex and Dose Independence: Protection was observed in both male and female hosts and was effective against both low ($10^3$) and high ($10^5$) challenge doses, though higher doses resulted in slightly higher residual burden.
• Buffer Effect: Formulations prepared in High Salt Buffer (300 mM NaCl) induced significantly higher antibody titers and better transmission blocking than those in standard PBS.
• Dietary Impact: A high-salt diet (4% NaCl) did not negatively impact vaccine efficacy, suggesting the high-salt formulation is safe for field deployment via bait.

Mechanism of Action

• Transmission Interference: Vaccinated hosts had reduced Bb burden in tissues (skin, joints). Consequently, feeding ticks acquired fewer spirochetes.
• Tick-Host Axis: The vaccine reduced Bb load in larvae, which subsequently reduced the load in molted nymphs, and finally prevented transmission to the next vertebrate host.
• Sterilizing Immunity: While not always achieving complete sterilization (zero bacteria), the vaccine reduced pathogen load below the transmission threshold, effectively breaking the enzootic cycle.

5. Significance

• Public Health Impact: This approach offers a sustainable strategy to reduce Lyme disease incidence by targeting the reservoir host, circumventing the need for human compliance with vaccines or antibiotics.
• Scalability: The oral delivery system (potentially via bait pellets) is scalable for field deployment in endemic areas.
• Broad Applicability: The PBL platform is adaptable and could be modified to target other tick-borne pathogens (e.g., Anaplasma, Babesia) or coinfections, as it utilizes native antigenic compositions rather than single recombinant proteins.
• Safety: The use of purified, non-live antigens avoids the safety concerns associated with live-vector vaccines (e.g., vaccinia or E. coli based systems).
• Long-term Protection: The demonstration of protection lasting up to 10 months with a single dose addresses a major hurdle in reservoir vaccination: the need for frequent boosting in wild populations.

In conclusion, the study establishes PBL+rCOM as a highly promising, pathogen-derived, oral biologic capable of disrupting the Lyme disease enzootic cycle by inducing durable, transmission-blocking immunity in reservoir hosts.